AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8557011 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 56
Study 1792341 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin refrigerant/anesthetic
Number of subjects: 60
Study 1792341 — intervention group
Group type: COMPARATOR
Intervention: Compressed air (Control)
Number of subjects: 60
Study 7275464 — intervention group
Group type: EXPERIMENTAL
Intervention: 320 kcal diet
Number of subjects: 0
Study 7275464 — intervention group
Group type: EXPERIMENTAL
Intervention: 320 kcal diet with 75 micrograms of T3 daily
Number of subjects: 0
Study 7275464 — intervention group
Group type: COMPARATOR
Intervention: Non-obese controls
Number of subjects: 0
Study 30736834 — intervention group
Group type: EXPERIMENTAL
Intervention: VIA Family intervention
Number of subjects: 100
Study 30736834 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 100
Study 30392276 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE with bleomycin, pirarubicin, oxaliplatin, and fluorouracil
Number of subjects: 160
Study 30392276 — intervention group
Group type: COMPARATOR
Intervention: Control group: TACE with pirarubicin, oxaliplatin, and fluorouracil
Number of subjects: 160
Study 27059176 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behaviour therapy (ICBT)
Number of subjects: 879
Study 27059176 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise (PE)
Number of subjects: 879
Study 27059176 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 879
Study 24165020 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone 2% transdermal gel
Number of subjects: 139
Study 24165020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 22153256 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin reinitiation in-hospital
Number of subjects: 284
Study 22153256 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin reinitiation in selected patients
Number of subjects: 284
Study 22153256 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with restarting warfarin
Number of subjects: 284
Study 22153256 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial international normalized ratio > 3.0
Number of subjects: 284
Study 22153256 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater stroke severity
Number of subjects: 284
Study 22153256 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraventricular hemorrhage
Number of subjects: 284
Study 19948753 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted physiotherapy (T; n = 30)
Number of subjects: 57
Study 19948753 — intervention group
Group type: COMPARATOR
Intervention: Generalized physiotherapy (G; n = 27)
Number of subjects: 57
Study 17714121 — intervention group
Group type: EXPERIMENTAL
Intervention: LC‐SSW‐UVB
Number of subjects: 143
Study 17714121 — intervention group
Group type: COMPARATOR
Intervention: UVB
Number of subjects: 143
Study 16315785 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 800 microg daily for 6 months
Number of subjects: 15
Study 16315785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 12455155 — intervention group
Group type: EXPERIMENTAL
Intervention: D-003 50 mg
Number of subjects: 60
Study 12455155 — intervention group
Group type: EXPERIMENTAL
Intervention: D-003 50 mg/day
Number of subjects: 60
Study 12455155 — intervention group
Group type: EXPERIMENTAL
Intervention: D-003 5, 25 and 50 mg/day
Number of subjects: 60
Study 12455155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 10600434 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly mailed smoking cessation intervention (personalized letter and self-help manual)
Number of subjects: 1858
Study 10600434 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1858
Study 8749687 — intervention group
Group type: EXPERIMENTAL
Intervention: Modeled bicarbonate dialysis (M; 28 mmol/L rising to 35 mmol/L at 3 h, 40 mmol/L at 4 h)
Number of subjects: 9
Study 8749687 — intervention group
Group type: EXPERIMENTAL
Intervention: High bicarbonate dialysis (H; 40 mmol/L)
Number of subjects: 9
Study 8749687 — intervention group
Group type: COMPARATOR
Intervention: Standard bicarbonate dialysis (S; dialysate HCO3- 30 to 34 mmol/L)
Number of subjects: 9
Study 8749687 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (S, H, M)
Number of subjects: 9
Study 2344857 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of 1.5 mg digoxin over 6 hours
Number of subjects: 11
Study 2344857 — intervention group
Group type: COMPARATOR
Intervention: Bolus injections of 0.5 mg digoxin 8 hours apart (three injections)
Number of subjects: 11
Study 2344857 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 11
Study 7407759 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPY administered via single iv bolus
Number of subjects: 26
Study 7407759 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPY administered via intermittent 5-day bolus
Number of subjects: 26
Study 7407759 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPY administered via 5-day continuous infusion
Number of subjects: 26
Study 7407759 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPY
Number of subjects: 26
Study 30177490 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotoxine mesylate 2.5 mg orally twice daily
Number of subjects: 30
Study 30177490 — intervention group
Group type: COMPARATOR
Intervention: Dihydroergotoxine mesylate
Number of subjects: 30
Study 27996280 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized MgSO₄
Number of subjects: 28
Study 27996280 — intervention group
Group type: COMPARATOR
Intervention: Intravenous MgSO₄
Number of subjects: 28
Study 25838291 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) exposure in the first trimester
Number of subjects: 12888
Study 25838291 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine/lamivudine/ritonavir-boosted lopinavir (LPV/r)
Number of subjects: 12888
Study 25838291 — intervention group
Group type: COMPARATOR
Intervention: LPV/r
Number of subjects: 12888
Study 25838291 — intervention group
Group type: EXPERIMENTAL
Intervention: ZDV exposure
Number of subjects: 12888
Study 24219370 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrageenan nasal spray, applied three times daily for seven days
Number of subjects: 211
Study 24219370 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrageenan nasal spray
Number of subjects: 211
Study 24219370 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 211
Study 21425952 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanitary pads with a nonwoven unique surface sheet
Number of subjects: 54
Study 21425952 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanitary pads with a perforated film
Number of subjects: 54
Study 19729979 — intervention group
Group type: COMPARATOR
Intervention: Weekly docetaxel 40 mg/m² (group A)
Number of subjects: 75
Study 19729979 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly docetaxel 35 mg/m² with gemcitabine 600 mg/m² (group B)
Number of subjects: 75
Study 16424649 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous anti-D (50 microg/kg i.v. initially, with repeated doses every 4 weeks for 12 patients)
Number of subjects: 34
Study 16424649 — intervention group
Group type: COMPARATOR
Intervention: Low-dose intravenous immunoglobulin (IVIG, 250 mg/kg for 2 consecutive days)
Number of subjects: 34
Study 11006039 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m², Paclitaxel 200 mg/m², Cyclophosphamide 500 mg/m² with G-CSF 300 microg daily for 5 days, followed by Carboplatin AUC-5 and Paclitaxel 135 mg/m²
Number of subjects: 30
Study 8699774 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 1% eyedrops (Chibro‐Amuno ‐3)
Number of subjects: 90
Study 8699774 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 0.1% eyedrops (Voltaren ophtha)
Number of subjects: 90
Study 8699774 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 0.03% eyedrops (Ocuflur)
Number of subjects: 90
Study 1803242 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% terbinafine cream
Number of subjects: 40
Study 1803242 — intervention group
Group type: COMPARATOR
Intervention: 1% bifonazole cream
Number of subjects: 40
Study 6337767 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of insulin [2.5 units h‐1 (m2 of body surface area)‐1]
Number of subjects: 6
Study 6337767 — intervention group
Group type: COMPARATOR
Intervention: Control (no insulin)
Number of subjects: 6
Study 6337767 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous angiotensin II (20 ng min‐1 kg‐1) with insulin
Number of subjects: 6
Study 6337767 — intervention group
Group type: COMPARATOR
Intervention: Intravenous angiotensin II (20 ng min‐1 kg‐1) without insulin
Number of subjects: 6
Study 31554423 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg loading dose, 90 mg twice daily thereafter)
Number of subjects: 120
Study 31554423 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (300 to 600 mg loading dose, 75 mg daily thereafter)
Number of subjects: 120
Study 29477989 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tidal volume ventilation (ARMA trial)
Number of subjects: 1022
Study 29477989 — intervention group
Group type: EXPERIMENTAL
Intervention: Low positive end-expiratory pressure (ALVEOLI trial)
Number of subjects: 1022
Study 29477989 — intervention group
Group type: EXPERIMENTAL
Intervention: Class 2 (from latent class analysis)
Number of subjects: 1022
Study 26143741 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.2 g marine n-3 polyunsaturated fatty acids (PUFA)
Number of subjects: 92
Study 26143741 — intervention group
Group type: COMPARATOR
Intervention: Control oil (thistle oil)
Number of subjects: 92
Study 25238769 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Clinical Prediction Rule (iCPR)
Number of subjects: 0
Study 22341868 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 200mg daily for 12 weeks
Number of subjects: 28
Study 22341868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 19541675 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic bubble trap (DBT)
Number of subjects: 143
Study 19541675 — intervention group
Group type: EXPERIMENTAL
Intervention: Embol-X
Number of subjects: 143
Study 19541675 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional device)
Number of subjects: 143
Study 19541675 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 143
Study 17343662 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 44
Study 17343662 — intervention group
Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 44
Study 15881488 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone monotherapy
Number of subjects: 0
Study 15881488 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone monotherapy and pioglitazone plus sulfonylurea
Number of subjects: 0
Study 15881488 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone plus metformin
Number of subjects: 0
Study 15881488 — intervention group
Group type: COMPARATOR
Intervention: Metformin monotherapy
Number of subjects: 0
Study 15881488 — intervention group
Group type: COMPARATOR
Intervention: Sulfonylurea monotherapy
Number of subjects: 0
Study 15881488 — intervention group
Group type: COMPARATOR
Intervention: Sulfonylurea plus metformin
Number of subjects: 0
Study 12078335 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbolithium Once‐A‐Day (600 mg)
Number of subjects: 18
Study 12078335 — intervention group
Group type: COMPARATOR
Intervention: Standard Carbolithium (300 mg b.i.d.)
Number of subjects: 18
Study 12038471 — intervention group
Group type: COMPARATOR
Intervention: Bread made with white flour
Number of subjects: 26
Study 12038471 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole wheat bread
Number of subjects: 26
Study 12038471 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine ground whole wheat bread
Number of subjects: 26
Study 7658536 — intervention group
Group type: EXPERIMENTAL
Intervention: RigiScan monitoring
Number of subjects: 521
Study 31676301 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS over left VLPFC
Number of subjects: 90
Study 31676301 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 90
Study 31676301 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS over right VLPFC
Number of subjects: 90
Study 30887708 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated and humidified low flow nasal cannula (HHLFNC), <4 liters per minute (LPM) oxygen
Number of subjects: 32
Study 30887708 — intervention group
Group type: COMPARATOR
Intervention: Standard dry oxygen (control)
Number of subjects: 32
Study 30887708 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated and humidified low flow nasal cannula (HHLFNC)
Number of subjects: 32
Study 26294281 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative hand reflexology
Number of subjects: 100
Study 26294281 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 100
Study 23456673 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene gel (3.7 g applied once daily)
Number of subjects: 0
Study 23456673 — intervention group
Group type: COMPARATOR
Intervention: Tazarotene foam (3.7 g applied once daily)
Number of subjects: 0
Study 23456673 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene gel
Number of subjects: 0
Study 23456673 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene foam and gel
Number of subjects: 0
Study 21241910 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine-timolol fixed combination, 1 drop immediately after surgery
Number of subjects: 58
Study 21241910 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 58
Study 19195263 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular aerobic physical training during cardiovascular rehabilitation program for 6 weeks
Number of subjects: 52
Study 19195263 — intervention group
Group type: COMPARATOR
Intervention: Sedentary lifestyle group (control)
Number of subjects: 52
Study 17825150 — intervention group
Group type: EXPERIMENTAL
Intervention: CTX + TBI
Number of subjects: 32
Study 17825150 — intervention group
Group type: COMPARATOR
Intervention: CTX + ATG
Number of subjects: 32
Study 15106795 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary-care centers for diagnosis and follow-up
Number of subjects: 1000
Study 15106795 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug prescription patterns
Number of subjects: 1000
Study 15106795 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultations and medications
Number of subjects: 1000
Study 11252223 — intervention group
Group type: EXPERIMENTAL
Intervention: Up-to-datedness score
Number of subjects: 106
Study 11252223 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriateness score
Number of subjects: 106
Study 11252223 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraclass correlation for up-to-datedness
Number of subjects: 106
Study 11252223 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraclass correlation for inappropriateness
Number of subjects: 106
Study 11252223 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraclass correlation for preventive maneuvers
Number of subjects: 106
Study 11252223 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample size requirements
Number of subjects: 106
Study 9850899 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia (oxybuprocaine 0.4% drops)
Number of subjects: 100
Study 9850899 — intervention group
Group type: COMPARATOR
Intervention: Peribulbar anesthesia (lidocaine 2% and bupivacaine 0.5% with hyaluronidase)
Number of subjects: 100
Study 7861719 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin at an average dose of 3.9 mg/kg/day for up to three years
Number of subjects: 19
Study 7861719 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin treatment continued for an additional two years
Number of subjects: 19
Study 7861719 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin treatment
Number of subjects: 19
Study 2682864 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol inhalation of salbutamol (SAL)
Number of subjects: 19
Study 2682864 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol inhalation of N‐acetyl cysteine (AC)
Number of subjects: 19
Study 2682864 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy (CPT)
Number of subjects: 19
Study 2682864 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with aerosol inhalation of SAL and AC followed by CPT (COMB)
Number of subjects: 19
Study 412450 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of sodium etidronate (EHDP)/kg body weight ‐ day for 6 to 24 months
Number of subjects: 109
Study 412450 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of sodium etidronate (EHDP)/kg body weight ‐ day for 6 to 24 months
Number of subjects: 109
Study 412450 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of sodium etidronate (EHDP)/kg body weight ‐ day for 6 to 24 months
Number of subjects: 109
Study 412450 — intervention group
Group type: EXPERIMENTAL
Intervention: Second course of EHDP
Number of subjects: 109
Study 31203381 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaporative coolants
Number of subjects: 63
Study 31203381 — intervention group
Group type: COMPARATOR
Intervention: Ice packs
Number of subjects: 63
Study 29070643 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional bracing
Number of subjects: 330
Study 29070643 — intervention group
Group type: COMPARATOR
Intervention: Plaster cast immobilisation
Number of subjects: 330
Study 29070643 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional bracing and Plaster cast immobilisation
Number of subjects: 330
Study 25777975 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skill training and parent training (8-week sessions)
Number of subjects: 48
Study 25777975 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 48
Study 23448807 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine
Number of subjects: 196
Study 23448807 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine plus AGS-1C4D4
Number of subjects: 196
Study 21368751 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Number of subjects: 0
Study 21368751 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 0
Study 18213728 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-surgery tongue velocity during speech
Number of subjects: 10
Study 18213728 — intervention group
Group type: COMPARATOR
Intervention: Control group (6 normal adults)
Number of subjects: 10
Study 17302257 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfuvirtide (ENF) 90 mg (1.0 ml)
Number of subjects: 30
Study 17302257 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfuvirtide (ENF) 45 mg (2 x 0.5 ml)
Number of subjects: 30
Study 17302257 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection vehicle (ENF buffer minus ENF)
Number of subjects: 30
Study 17302257 — intervention group
Group type: COMPARATOR
Intervention: Control (Cohort II - ENF-naive)
Number of subjects: 30
Study 15017494 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg
Number of subjects: 40
Study 15017494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10875491 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical beclomethasone treatment
Number of subjects: 26
Study 10875491 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 26
Study 9165598 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin treatment
Number of subjects: 3521
Study 1589705 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline triple therapy (with bismuth subcitrate and metronidazole)
Number of subjects: 73
Study 1589705 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline HCl triple therapy (with bismuth subcitrate and metronidazole)
Number of subjects: 73
Study 3928490 — intervention group
Group type: EXPERIMENTAL
Intervention: LGX (laevulose 20%, glucose 10%, xylitol 10%)
Number of subjects: 6
Study 3928490 — intervention group
Group type: COMPARATOR
Intervention: Glucose 50%
Number of subjects: 6
Study 3928490 — intervention group
Group type: EXPERIMENTAL
Intervention: LGX regime alone
Number of subjects: 6
Study 31995720 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 0
Study 31995720 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study 29754384 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 80
Study 29754384 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 80
Study 27837181 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided foam sclerotherapy (USGFS) of the GSV
Number of subjects: 326
Study 25135804 — intervention group
Group type: EXPERIMENTAL
Intervention: Font-enlarged labels
Number of subjects: 110
Study 25135804 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictogram-incorporated labels
Number of subjects: 110
Study 25135804 — intervention group
Group type: COMPARATOR
Intervention: Standard labels
Number of subjects: 110
Study 22527813 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication therapy (group 1)
Number of subjects: 99
Study 22527813 — intervention group
Group type: COMPARATOR
Intervention: H. pylori eradication therapy (group 2)
Number of subjects: 99
Study 22527813 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 3)
Number of subjects: 99
Study 21302485 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine combined with Chaihu Xiaoyao Mixture (CXM)
Number of subjects: 190
Study 21302485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 18006206 — intervention group
Group type: EXPERIMENTAL
Intervention: Tray based whitening system (Colgate Visible White PF Mint) using a 6% hydrogen peroxide gel applied in the tray twice daily for 30 min
Number of subjects: 49
Study 18006206 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 49
Study 14980755 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 63